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ABSTRACT
Dabigatran overload has been reported in acute kidney injury (AKI), leading to occasional major bleeding. Haemodialysis
(HD) was the method used for reversing dabigatran anticoagulant effects before the approval of idarucizumab, which is now
indicated for dabigatran reversal in major bleeding or surgical emergencies. There have been reports of rebound of
dabigatran levels following idarucizumab administration in AKI, requiring HD to achieve effective dabigatran clearance.
However, a decisional algorithm to individualize treatments for dabigatran overload seems lacking. We present a case of
dabigatran accumulation in obstructive AKI with minor bleeding that was successfully treated with HD and tranexamic acid
without using idarucizumab, and propose a decision-making algorithm including different pathways in the management of
suspected dabigatran overload in AKI.
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INTRODUCTION
Dabigatran is a direct thrombin inhibitor, used in the prevention
of stroke in atrial fibrillation (AF) and in the management and
prevention of venous thromboembolism. Dabigatran is mainly
eliminated by renal excretion, and hence it is contraindicated in
patients with creatinine clearance (CrCl) of <30 mL/min [1].
Dabigatran increases the risk for bleeding, particularly in acute
kidney injury (AKI) [2].
Before 2015, haemodialysis (HD) was unique rescue therapy
for urgent dabigatran reversal, e.g. in the setting of bleeding
and/or emergent surgery and/or dabigatran overload in AKI,
since dabigatran has a low molecular weight and weak protein-
binding properties [3].
In 2015, idarucizumab, a humanized monoclonal antibody
directed against free and thrombin-bound dabigatran, was ap-
proved to address the need for an agent that can reverse dabiga-
tran’s anticoagulant effects [4]. Rebound in circulating
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dabigatran levels after idarucizumab administration was
reported in AKI, conditioning refractory anticoagulation [2], re-
quiring HD for dabigatran clearance [2, 5]. Several factors may
account for the rebound increases in dabigatran levels in AKI,
including redistribution of dabigatran from the extravascular to
vascular space, obesity and protracted dabigatran assumption
in, often asymptomatic, renal function decline [2].
A systematic approach should guide the decision-making
process to rapidly determine the efficacy of idarucizumab and
HD in individual patients, leading to cost-effective treatment of
dabigatran overload and its complications in AKI.
We report a case of dabigatran overload with minor
bleeding, as a result of obstructive AKI, which was success-
fully treated with six HD sessions and tranexamic acid, with-
out using idarucizumab. We therefore propose an algorithm
for managing patients with dabigatran overload in AKI
(Figure 1).
CASE PRESENTATION
An 82-year-old man with a ‘laboratory’ diagnosis of AKI [serum
creatinine (sCr) 14 mg/dL] was admitted to the emergency room.
His clinical history included AF (CHA2DS2-VASc¼ 3), prostatic
adenocarcinoma, chronic kidney disease stage G3b (sCr 1.9 mg/
dL, Cockcroft–Gault estimated CrCl 30 mL/min), arterial hyper-
tension and chronic anaemia [haemoglobin (Hb) 11.6 g/dL
2 months earlier]. He received chronic treatment with dabiga-
tran 100 mg twice daily, digoxin, hydrochlorothiazide, olmesar-
tan, bisoprolol, febuxostat and dutasteride. Biochemistry
investigations on admission confirmed AKI, acute anaemia
Suspected Dabigatran Overload in the presence 
of eGFR < 30 ml/min
Major Bleeding Surgical Urgency Dialysis Urgency
Consider
- Idarucizumab
- Tranexamic acid 
Consider US-assisted venous catheter placement for HD 
- Any anatomical abnormality at US examination?
- Any technical difficulty expected?
(beside bleeding risk due to dabigatran overload)
Yes: consider idarucizumab before placing HD venous catheter
No: administer tranexamic acid 1 g iv, then proceed with US-assisted HD venous catheter
Administer idarucizumab in the case of major bleeding occurred during HD catheter
placement (whenever not administered before placing)
Evaluate
- Risk of dabigatran rebound and re-worsening of bleeding risk within the next 6-12 hours
(especially in CKD, chronic dabigatran assumption, obesity, expected delayed recovery of 
renal function)
Renal Function at Admission
(eGFR < 30 ml/min)
sCr____BUN____eGFR___Urine outpt______
K_____Ca_____Na____
pH_____Bic____BE____pCO2___Lactate__
AKI CKD AKI over CKD   
Dabigatran Therapy & Coagulation State at Admission
Dabigatran daily dose (mg/day)_______Indication__________________
Date of dabigatran start____/____/____    last assumption ____/____/____
Hb____PLT____ aPTT (sec)_____aPTT Ratio ____PT (sec)_____aPT INR_____
Dabigatran circulating levels ___________________________
Chronic Poisoning   
High efficient dialysis (modality and dose)
Hemodynamic stability
No          Yes
Probability of surgical revision within 72 hours
High                         Low
Daily pre dilution HDF without heparin
At least 3 h/session
Qb up to 300 ml/min whenever achievable
Qd up to 700 ml/min whenever achievable
72h CRRT course
without heparin
high efficiency
(CVVHD-CVVHDF with Citrate)
A single factor in favour of CRRT may suggest CRRT as the treatment of choice
Re-Assess dabigatran circulating levels
- Goals: a) quantify rebound (expression of residual extravascular dabigatran load)
b) plan the number of next HD sessions, expected to be required for completing
dabigatran clearance
- Re-assess dabigatran at 6 and 12 hours after idarucizumab administration
- Re-assess dabigatran circulating levels before & after the first HD session and the day after, 
then before every next HD session
- 50% reduction of circulating levels is expected after each 4 hours of high efficient HDF2
- 80% reduction of circulating dabigatran levels is expected after 30 hours of CRRT2
monitor aPTT every 12 hours and assess dabigatran at the end CRRT course (72 h at 
maximum) or in the case of bleeding
Minor Bleeding
Consider
- Tranexamic acid 
Operating
Room
Yes
No
R
is
k
as
se
ss
m
en
t
Pr
es
en
ta
tio
n
Tr
ea
tm
en
to
pt
io
ns
&
m
on
ito
rin
g
◻ ◻ ◻
◻ ◻
FIGURE 1: Decision-making algorithm including different pathways in the management of suspected dabigatran overload in AKI. Dabigatran overload should be sus-
pected in patients treated with dabigatran with an eGFR<30 mL/min. The algorithm comprises three major steps: (i) ‘Presentation’: two boxes summarize essential
data on renal function, electrolyte levels, dabigatran treatment, dabigatran circulating levels, coagulation state and anaemia; (ii) ‘Risk assessment’: this includes four
conditions that define the risk severity related to dabigatran overload; (iii) ‘Treatment options & monitoring’: in the presence of major bleeding (red pathway) or surgi-
cal urgency (violet pathway), idarucizumab and tranexamic acid should be considered as first-choice treatment, following evaluation of factors favouring dabigatran
rebound with refractory anticoagulation (brown box) that may require HD within next 6–12 h (green pathway); in the presence of minor bleeding (orange pathway),
treatment with tranexamic acid may be sufficient, without the need for idarucizumab, but still requiring assessment of factors favouring dabigatran rebound with re-
fractory anticoagulation requiring HD (brown box); dialysis urgency (green pathway), due to severity of AKI and related complications, will require venous dialysis cath-
eter placement; suggestions related to dialysis catheter placement, choice of dialysis technique, dialysis prescription and monitoring of dabigatran and coagulation
profile are summarized in green boxes. aPTT, activated partial thromboplastin time; BE, base excess; Bic, serum bicarbonate; Ca, serum calcium; CKD, chronic kidney
disease; CRRT, continuous renal replacement therapy; CVVHD, continuous veno-venous haemodialysis; CVVHDF, continuous veno-venous haemodiafiltration; eGFR,
estimated glomerular filtration rate; Hb, haemoglobin; INR, international normalized ratio; K, serum potassium; Na, serum sodium; PLT, platelet count; PT, prothrom-
bin time; Qb, dialysis blood flow rate; Qd, dialysate flow rate; Ratio, aPTT ratio.
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with signs of anticoagulation (Supplementary data, Figure S1)
and mild metabolic acidosis with normokalaemia (bicarbonate
19 mmol/L, lactate 1.23 mmol/L, potassium 4.8 mmol/L).
Ultrasound (US) examination revealed bilateral hydrouretero-
nephrosis with stenotic terminal ureters. Dabigatran, digoxin
and olmesartan were discontinued. The patient was transferred
to the Medicine Unit, and was referred for bilateral urostomy
placement after dabigatran washout. Within the next 48 h, epi-
staxis with worsening anaemia (Hb 7.5 g/dL) occurred, requiring
blood transfusion, intravenous (IV) tranexamic acid and nasal
tamponade. Two days post-treatment, the patient was asymp-
tomatic, showing no signs of heart failure, with a diuresis rate
of 0.5 L/24 h achieved with IV furosemide. Dabigatran levels
were high (666 ng/mL), whereas other biochemical parameters
remained mainly unchanged (Supplementary data, Figure S1).
Following a multidisciplinary discussion between the nephrolo-
gist and the internist, HD treatment was preferred for removal
of dabigatran before urological intervention, thus circumvent-
ing the need for idarucizumab in case of major bleeding, due to:
(i) the high risk for dabigatran rebound after idarucizumab ad-
ministration in severe AKI; (ii) the patient’s lengthy exposure to
dabigatran; (iii) the absence of major uncontrolled bleeding; and
(iv) the absence of other surgical emergencies. Bleeding risk re-
lated to US-guided placement of a temporary dialysis catheter
in the femoral vein was considered acceptable without the need
for idarucizumab, based on the absence of increased anatomical
risks at US evaluation and with the expectation of effective pri-
mary haemostasis achievable with IV tranexamic acid adminis-
tration if required. A temporary dialysis catheter was placed in
the femoral vein without complications. On Day 2 post-catheter
placement, 3-h haemodiafiltration (HDF) without heparin was
performed, leading to 50% reduction in dabigatran levels
(366 ng/mL). On Day 3, dabigatran levels were still elevated
(355 ng/mL). Five further HDF sessions were undertaken for ade-
quate dabigatran clearance (35 ng/mL), which was achieved on
Day 9. Bilateral urostomy placing was delayed on Day 10, due to
restored diuresis and metabolic control as a result of HD treat-
ment and complete dabigatran clearance achieved on Day 9
(Supplementary data, Figure S1). Calciparin was introduced on
Day 11. The patient was discharged on Day 14 (sCr 3.6 mg/dL).
Warfarin was commenced 1 month later. During the 4 months
following discharge, the patient was readmitted three times to
the urology unit for urostomy replacement (the left urostomy
was not further replaced, due to resolved left hydronephrosis)
and due to one episode of urinary infection. On Day 121, sCr
returned to 1.9 mg/dL. The estimated cost related to treatment
with HDF and tranexamic was e1860, compared with a cost of
e4738 for two minimal doses of idarucizumab, which might
have been inadequate for complete dabigatran clearance.
DISCUSSION
The present case highlights the following important points: (i) a
one-size-fits-all approach may not be appropriate in terms of
the efficacy and safety of interventions to treat dabigatran over-
load in AKI patients; (ii) a systematic algorithm for guiding an
individualized approach is recommended (Figure 1); (iii) HD
remains a strong treatment option for managing dabigatran
overload in severe AKI, even in the era of idarucizumab; (iv) tra-
nexamic acid is effective in controlling the bleeding risk of un-
complicated US-guided placement of venous femoral dialysis
catheters in cases of dabigatran overload; and (v) daily HD or
continuous renal replacement therapy may be required for ef-
fective dabigatran clearance in AKI, guided by continuous moni-
toring of dabigatran circulating levels.
PATIENT CONSENT
The patient and his family gave informed consent to publish
this case.
SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
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